home > ict > autumn 2019 > the spirit of radical integration
International Clinical Trials

The Spirit of Radical Integration

Patricia Leuchten, Founder and CEO of The Avoca Group, asked people at a recent pharmaceutical industry conference to raise their hands if they felt their company was ‘pretty good’ − not great, just pretty good − at dealing with the risks inherent in the clinical trial process.

Not a single hand went up.

Her goal is to one day ask again and see every hand raised. Leuchten’s passion, and Avoca’s mission, is for an industry that now struggles to manage risks and design quality into clinical trials to develop a more proactive mindset and overcome communication gaps in bringing life-changing products to patients. As she puts it, “It’s the difference between putting out fires and preventing fires”. Clinical trials are, of course, never free of risks, especially with increasingly complex therapies, trial designs, and operating models. They all contain elements of the unknown that no amount of preparation can completely erase. However, risks can be proactively identified, managed, and mitigated, and that’s where Avoca comes in.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the company

The Avoca Group is a life science consulting firm dedicated to improving quality and compliance in clinical trial execution. Since 2011, the AQC, a collaborative of over 100 pharma, biotech, CRO, and clinical service provider companies, has led the industry in developing practical solutions for improving quality and execution in clinical trials. Companies benefit from Avoca’s insightful research, deep subject matter expertise, industry-leading approaches, and technology. Avoca offers platforms and tailored solutions to help clinical research companies increase quality, ensure compliance, and improve efficiency so that medicines can reach patients faster.
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines

Ajdovšcina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement